Multiplex Construction Canada and McMaster Innovation Park celebrate the OmniaBio project delivery
by CM staff
OmniaBio, planned at 400,000 square feet, will be the largest CDMO exclusively manufacturing for cell and gene therapies in Canada.
Representatives from Multiplex Construction Canada and McMaster Innovation Park (l-r) Brian Farrelly, Scott Rasmussen, Atiaan Stander, Sandra Tran, Frances Grabowski, Ty J. Shattuck, Terry Olynyk and Pedro Duarte stopped for a quick photo-op during a tour of the OmniaBio facility. (CNW Group/McMaster Innovation Park)
HAMILTON — One year following the initiation of construction on the OmniaBio B Building at McMaster Innovation Park (MIP), the Multiplex Construction Canada team announced the successful delivery of the OmniaBio B Base Build. Executed under the innovative Integrated Project Delivery (IPD) method, this project showcases an on-time and on-budget project delivery, providing the core and shell infrastructure for accessibility to MIP and its partners, OmniaBio.
“The OmniaBio project exemplifies the efficacy of Integrated Project Delivery. Our vision was to streamline the construction process and expedite the development of a cutting-edge CDMO infrastructure,” said Frances Grabowski, Vice President of Development and Design at MIP. “Through effective collaboration and an unwavering commitment to excellence, we successfully realized our objectives.”
The IPD approach facilitated communication and cooperation among all stakeholders, resulting in the delivery of the building.
President and Managing Director of Multiplex Construction Canada Terry Olynyk also shared that he takes “immense pride in the dedication and hard work demonstrated by our entire construction team. Their tireless efforts have not only led to the successful completion of the OmniaBio B Building project but have also reinforced our steadfast commitment to delivering construction projects of the highest quality. The collaboration fostered through the Integrated Project Delivery (IPD) approach has been instrumental in our success. We are delighted to celebrate this significant milestone alongside MIP, trade partners, consultants, and the broader community.”
OmniaBio, planned at 400,000 square feet, will be the largest CDMO exclusively manufacturing for cell and gene therapies in Canada. MIP has now delivered the core and shell of the first phase, 90,000 SF. The building’s occupancy is projected for summer 2024.
